Abbott Laboratories (ABT)
Abbott Laboratories Statistics
Share Statistics
Abbott Laboratories has 1.73B shares outstanding. The number of shares has increased by -0.31% in one year.
| Shares Outstanding | 1.73B |
| Shares Change (YoY) | -0.31% |
| Shares Change (QoQ) | -0.01% |
| Owned by Institutions (%) | 77.44% |
| Shares Floating | 1.72B |
| Failed to Deliver (FTD) Shares | 43.13K |
| FTD / Avg. Volume | 0.62% |
Short Selling Information
The latest short interest is 14.32M, so 0.83% of the outstanding shares have been sold short.
| Short Interest | 14.32M |
| Short % of Shares Out | 0.83% |
| Short % of Float | 0.83% |
| Short Ratio (days to cover) | 3.01 |
Valuation Ratios
The PE ratio is 14.62 and the forward PE ratio is 22.46. Abbott Laboratories's PEG ratio is 0.11.
| PE Ratio | 14.62 |
| Forward PE | 22.46 |
| PS Ratio | 4.67 |
| Forward PS | 3.9 |
| PB Ratio | 4.11 |
| P/FCF Ratio | 30.84 |
| PEG Ratio | 0.11 |
Enterprise Valuation
Abbott Laboratories has an Enterprise Value (EV) of 203.28B.
| EV / Sales | 4.85 |
| EV / EBITDA | 18.76 |
| EV / EBIT | 23.75 |
| EV / FCF | 32.01 |
Financial Position
The company has a current ratio of 1.67, with a Debt / Equity ratio of 0.32.
| Current Ratio | 1.67 |
| Quick Ratio | 1.23 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | 1.39 |
| Debt / FCF | 2.37 |
| Interest Coverage | 12.21 |
Financial Efficiency
Return on Equity is 28.12% and Return on Invested Capital is 18.97%.
| Return on Equity | 28.12% |
| Return on Assets | 16.46% |
| Return on Invested Capital | 18.97% |
| Revenue Per Employee | $367.98K |
| Profits Per Employee | $117.56K |
| Employee Count | 114,000 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 3.02 |
Taxes
| Income Tax | -6.39B |
| Effective Tax Rate | -91.1% |
Stock Price Statistics
The stock price has increased by 19.49% in the last 52 weeks. The beta is 0.8, so Abbott Laboratories's price volatility has been higher than the market average.
| Beta | 0.8 |
| 52-Week Price Change | 19.49% |
| 50-Day Moving Average | 131.04 |
| 200-Day Moving Average | 116.96 |
| Relative Strength Index (RSI) | 53.74 |
| Average Volume (20 Days) | 6.93M |
Income Statement
In the last 12 months, Abbott Laboratories had revenue of 41.95B and earned 13.4B in profits. Earnings per share was 7.74.
| Revenue | 41.95B |
| Gross Profit | 23.24B |
| Operating Income | 6.83B |
| Net Income | 13.4B |
| EBITDA | 10.83B |
| EBIT | 7.57B |
| Earnings Per Share (EPS) | 7.74 |
Balance Sheet
The company has 7.62B in cash and 15.02B in debt, giving a net cash position of -7.41B.
| Cash & Cash Equivalents | 7.62B |
| Total Debt | 15.02B |
| Net Cash | -7.41B |
| Retained Earnings | 47.26B |
| Total Assets | 81.41B |
| Working Capital | 9.5B |
Cash Flow
In the last 12 months, operating cash flow was 8.56B and capital expenditures -2.21B, giving a free cash flow of 6.35B.
| Operating Cash Flow | 8.56B |
| Capital Expenditures | -2.21B |
| Free Cash Flow | 6.35B |
| FCF Per Share | 3.67 |
Margins
Gross margin is 55.41%, with operating and profit margins of 16.27% and 31.95%.
| Gross Margin | 55.41% |
| Operating Margin | 16.27% |
| Pretax Margin | 16.72% |
| Profit Margin | 31.95% |
| EBITDA Margin | 25.83% |
| EBIT Margin | 16.27% |
| FCF Margin | 15.14% |
Dividends & Yields
ABT pays an annual dividend of $2.83, which amounts to a dividend yield of 1.73%.
| Dividend Per Share | $2.83 |
| Dividend Yield | 1.73% |
| Dividend Growth (YoY) | 7.27% |
| Payout Ratio | 37.04% |
| Earnings Yield | 6.84% |
| FCF Yield | 3.24% |
Analyst Forecast
The average price target for ABT is $135, which is 2.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $135 |
| Price Target Difference | 2.6% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
Stock Splits
The last stock split was on Jan 2, 2013. It was a forward split with a ratio of 5000:2399.
| Last Split Date | Jan 2, 2013 |
| Split Type | forward |
| Split Ratio | 5000:2399 |
Scores
| Altman Z-Score | 5.86 |
| Piotroski F-Score | 8 |